Skip to main content

Breadcrumb

  1. Home

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Portico NG Approval Study

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Portico NG Approval Study

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 40
  • Page 41
  • Page 42
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • …
  • Next page Next
  • Last page Last
Subscribe to